BANOOK GROUP partners with BEPATIENT to offer eCOA/ePRO solutions.
In the context of healthcare, an important challenge is how to ensure the continuity of clinical trials. In such trials, which are often very costly, the recruitment, adherence and retention of candidates are key. The main challenge is ensuring patient adherence within the constraints of their daily life. BANOOK GROUP and BEPATIENT have combined strengths to develop a new paradigm that helps keep patients connected through this necessary virtual experience.
BANOOK GROUP, leader in central lab services, has partnered with BEPATIENT, a pioneer in the development of patient-centric virtual trials and digital therapeutics solutions. This alliance will provide the healthcare ecosystem with new added-value solutions.
BANOOK GROUP has established expertise in Cardiac Safety, Central Imaging and Endpoint Adjudication, ensuring regulatory compliance in all therapeutic areas. Its medical and regulatory expertise, quality driven approach and team availability makes BANOOK GROUP a key player in clinical trials.
In the last couple of years, in response to demand for broader centralization, BANOOK GROUP decided to expand its activities to include eCOA/ePRO solutions, hence initiating the collaboration with BEPATIENT.
With its agile and innovative culture, BEPATIENT has spent more than ten years developing a proprietary patient-centric eHealth platform that enables direct-to-patient data collection solutions for Virtual Clinical Trials as well as Patient Support, Patient Engagement, Screening and Remote Monitoring solutions for new digital therapies.
In order to explain, in concrete terms, how to conduct virtual clinical trials in a rational and operational way, BANOOK GROUP and BEPATIENT will be co-hosting a workshop at the DIA 2021 Global Annual Meeting, on the subject of “Virtual Clinical Trials: how to manage direct to patient solutions, in real life?”
BANOOK GROUP and BEPATIENT combine their expertise, solutions (ePRO/eCOA/IA & IoTs integration) and state-of-the-art devices for an operational response that will ensure the success of direct-to-patient trials, in real life.
“We are delighted to be in a position to offer eCOA-ePRO Services solutions to our customers. BEPATIENT provides the ideal platform for BANOOK GROUP to continue development and deployment of standards that accelerate the clinical research process and provide a smooth transition to Virtual clinical trial”— Yasmin Khan, COO BANOOK GROUP.
“Since our creation in 2011, we have been solicited mainly by Pharma, MedTech and our CROs partners to provide Virtual Trial solutions for late phase studies. This new partnership with BANOOK GROUP is a great entry point into the highly coveted market of pre-registration studies. In addition, BANOOK GROUP’s Central Lab services will enable us to enhance our current value proposal for the European and North American market.” — FDS, CEO BEPATIENT.
About BEPATIENT
BEPATIENT is a French company that has been developing since 2011 a comprehensive and modular core platform, enabling patients to be connected at home to Healthcare Professionals and to generate value-added Real-World Evidence (RWE) data. The BEPATIENT portfolio of solutions is structured around two activities: Clinical Research digitalization via direct-to-patient virtual trials technologies (ePRO, eCOA, eConsent, integration of connected devices, eCRF, etc.) and Digital Therapeutics: evidence-based Companion Apps integrating symptom checking, management of treatment adherence, remote monitoring, eLearning, …
BEPATIENT’s activities are mainly concentrated in EMEA, with a wide range of therapeutic areas (inflammatory diseases, immunology, oncology, cardiometabolic, chronic pain, neurosciences…) in several languages.
Press contact: Audrey Cohuet | audrey.cohuet@bepatient.com |
About BANOOK GROUP
Since 1999, BANOOK GROUP is one of the few established international providers capable of supplying Cardiac Safety, Central Imaging, Endpoint Adjudication and eCOA solution services to pharmaceutical, medical device and biotech companies, CROs and nonprofit organizations. Our mission is to help our client invent tomorrow’s healthcare by using qualitative, reliable and innovative solutions in early to late stage clinical trials.
BANOOK GROUP has developed its own platform for data centralization, the ATRIUM suite and keep committed to innovation by mastering customized solutions.
The group operates on an international scale, maintaining offices at its headquarters in France and Canada.
Press contact: Alice Minetto | alice.minetto@banookgroup.com |